Utama › Kanser Endometrium › North Carolina › Durham
Kajian klinikal Kanser Endometrium di Durham, NC
16 kajian untuk Kanser Endometrium sedang mencari peserta di lokasi dalam dan sekitar Durham (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Tirzepatide in Obesity-Driven Endometrial Cancer
Mengambil pesertaFasa awal 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Mengambil pesertaFasa 2
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- Duke University, Durham
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Mengambil pesertaFasa 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Mengambil pesertaFasa 2
- Duke University Medical Center, Durham
DESTINY-PANTUMOUR04
Mengambil pesertaKajian pemerhatian
- Research Site, Durham
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Mengambil pesertaFasa 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Mengambil pesertaFasa 3
- Duke Cancer Institute ( Site 6049), Durham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Mengambil pesertaKajian pemerhatian
- UNC- Chapel Hill, Chapel Hill · 10 mi jauh
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Mengambil pesertaFasa 3
- Duke Cancer Institute, Durham
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Mengambil pesertaFasa 1
- Duke Cancer Institute, Durham
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Duke University, Durham
A Study of PHST001 in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Duke Cancer Institute, Durham
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Mengambil pesertaFasa 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Multimedia Aid for Genetic Testing in Gynecologic Oncology
Mengambil peserta
- Univeristy of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauh
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi jauh
Kajian Kanser Endometrium di bandar lain
- Houston, TX68 kajian
- New York City, NY52 kajian
- Boston, MA50 kajian
- Arlington, VA39 kajian
- Nashville, TN38 kajian
- Los Angeles, CA34 kajian
- St. Louis, MO29 kajian
- Philadelphia, PA28 kajian
- San Antonio, TX27 kajian
- Chicago, IL25 kajian
- Columbus, OH25 kajian
- Queens, NY25 kajian
Kajian lain di Durham
- Kanser Payudara63 kajian
- Kanser (semua jenis)58 kajian
- Kanser Paru-paru Bukan Sel Kecil39 kajian
- Mieloma Pelbagai37 kajian
- Kanser Metastatik33 kajian
- Leukemia Mieloid Akut33 kajian
- Kanser Paru-paru32 kajian
- Kanser Prostat32 kajian
- Kanser Kolorektal28 kajian
- Leukemia Limfositik Kronik27 kajian
- Kanser Ovari27 kajian
- Kegagalan Jantung26 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.